Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099685521> ?p ?o ?g. }
- W2099685521 endingPage "1046" @default.
- W2099685521 startingPage "1042" @default.
- W2099685521 abstract "No AccessJournal of UrologyAdult Urology1 Sep 2008Effect of Vardenafil on Blood Pressure Profile of Patients With Erectile Dysfunction Concomitantly Treated With Doxazosin Gastrointestinal Therapeutic System for Benign Prostatic Hyperplasiais accompanied byHow Many Drugs for LUTS Due to BPH are Too Many? Chi-Fai Ng, Annie Wong, Chi-Wai Cheng, Eddie Shu-Yin Chan, Hon-Ming Wong, and See-Ming Hou Chi-Fai NgChi-Fai Ng More articles by this author , Annie WongAnnie Wong More articles by this author , Chi-Wai ChengChi-Wai Cheng More articles by this author , Eddie Shu-Yin ChanEddie Shu-Yin Chan More articles by this author , Hon-Ming WongHon-Ming Wong More articles by this author , and See-Ming HouSee-Ming Hou More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2008.05.052AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated the effect of the combination of the doxazosin gastrointestinal therapeutic system and 10 mg vardenafil on the hemodynamic status of patients with benign prostatic hyperplasia and erectile dysfunction. Materials and Methods: This was a double-blinded, randomized, placebo controlled crossover trial. Patients with benign prostatic hyperplasia and erectile dysfunction treated with the doxazosin gastrointestinal therapeutic system on a regular basis, with no other antihypertensive events, were recruited. Subjects took 10 mg vardenafil or placebo in a randomized crossover fashion with a washout period of at least 7 days between each treatment. The supine and standing blood pressure of the subjects was recorded from 1 hour before to 6 hours after the administration of vardenafil or placebo. The primary outcome of the study was the maximal change in standing systolic blood pressure of the subjects from 1 half hour before to 6 hours after the administration of drugs. Results: A total of 37 patients, 25 (67.6%) and 12 (32.4%) on the doxazosin gastrointestinal therapeutic system at 4 mg and 8 mg, respectively, completed the trial. The combination drug therapy resulted in a maximal decrease in standing systolic blood pressure of 6.18 mm Hg (95% CI −12.02, −0.33; p = 0.039). Only 1 patient had an asymptomatic standing systolic blood pressure of less than 85 mm Hg. Otherwise no symptomatic hypotension or clinically significant adverse cardiovascular event was observed during the study. Conclusions: In patients on the doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia a single 10 mg dose of vardenafil had no symptomatic hemodynamic effects. References 1 : Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol2003; 44: 637. Google Scholar 2 : Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int2006; 97: 23. Google Scholar 3 : Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol2007; 51: 1717. Google Scholar 4 : Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res2002; 14: 50. Google Scholar 5 : Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and 2 alpha-blockers, doxazosin and tamsulosin, in healthy normotensive men. J Urol2004; 172: 1935. Link, Google Scholar 6 : Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology2006; 67: 1199. Google Scholar 7 : Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol2005; 96: 42M. Google Scholar 8 : Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology2004; 64: 998. Google Scholar 9 : Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol1999; 48: 678. Google Scholar 10 : Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res1999; 11: 319. Google Scholar 11 : Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol2001; 19: 32. Google Scholar 12 : Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol2005; 96: 313. Google Scholar 13 : State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology2004; 64: 1081. Google Scholar 14 : Central control of the cardiovascular and erection systems: possible mechanisms and interactions. Am J Cardiol2000; 86: 19F. Google Scholar 15 : Hypertension is associated with severe erectile dysfunction. J Urol2000; 164: 1188. Link, Google Scholar 16 : Effect of sidenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens2000; 18: 1865. Google Scholar 17 : Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med2005; 2: 856. Google Scholar 18 : Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int2006; 98: 1259. Google Scholar 19 : Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol2007; 177: 1401. Link, Google Scholar 20 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China© 2008 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology17 Jul 2008How Many Drugs for LUTS Due to BPH are Too Many? Volume 180Issue 3September 2008Page: 1042-1046 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordsadrenergic alpha-antagonistserectile dysfunctionphosphodiesterase inhibitorsprostatic hyperplasiaAcknowledgmentsDr. Lung-wai Chan provided advice on the initial study design.MetricsAuthor Information Chi-Fai Ng More articles by this author Annie Wong More articles by this author Chi-Wai Cheng More articles by this author Eddie Shu-Yin Chan More articles by this author Hon-Ming Wong More articles by this author See-Ming Hou More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2099685521 created "2016-06-24" @default.
- W2099685521 creator A5013752653 @default.
- W2099685521 creator A5032078035 @default.
- W2099685521 creator A5036447607 @default.
- W2099685521 creator A5063310045 @default.
- W2099685521 creator A5080622031 @default.
- W2099685521 creator A5089571151 @default.
- W2099685521 date "2008-09-01" @default.
- W2099685521 modified "2023-10-14" @default.
- W2099685521 title "Effect of Vardenafil on Blood Pressure Profile of Patients With Erectile Dysfunction Concomitantly Treated With Doxazosin Gastrointestinal Therapeutic System for Benign Prostatic Hyperplasia" @default.
- W2099685521 cites W1598325375 @default.
- W2099685521 cites W1986245915 @default.
- W2099685521 cites W1995256786 @default.
- W2099685521 cites W1995587221 @default.
- W2099685521 cites W2026641917 @default.
- W2099685521 cites W2030831900 @default.
- W2099685521 cites W2035776427 @default.
- W2099685521 cites W2038393150 @default.
- W2099685521 cites W2051838969 @default.
- W2099685521 cites W2053295331 @default.
- W2099685521 cites W2060960672 @default.
- W2099685521 cites W2069963496 @default.
- W2099685521 cites W2079630871 @default.
- W2099685521 cites W2121759271 @default.
- W2099685521 cites W2147450987 @default.
- W2099685521 cites W2148223588 @default.
- W2099685521 cites W2154024168 @default.
- W2099685521 cites W2160170325 @default.
- W2099685521 cites W2331319303 @default.
- W2099685521 cites W4253571104 @default.
- W2099685521 doi "https://doi.org/10.1016/j.juro.2008.05.052" @default.
- W2099685521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18639296" @default.
- W2099685521 hasPublicationYear "2008" @default.
- W2099685521 type Work @default.
- W2099685521 sameAs 2099685521 @default.
- W2099685521 citedByCount "20" @default.
- W2099685521 countsByYear W20996855212012 @default.
- W2099685521 countsByYear W20996855212013 @default.
- W2099685521 countsByYear W20996855212014 @default.
- W2099685521 countsByYear W20996855212016 @default.
- W2099685521 countsByYear W20996855212018 @default.
- W2099685521 countsByYear W20996855212020 @default.
- W2099685521 countsByYear W20996855212022 @default.
- W2099685521 crossrefType "journal-article" @default.
- W2099685521 hasAuthorship W2099685521A5013752653 @default.
- W2099685521 hasAuthorship W2099685521A5032078035 @default.
- W2099685521 hasAuthorship W2099685521A5036447607 @default.
- W2099685521 hasAuthorship W2099685521A5063310045 @default.
- W2099685521 hasAuthorship W2099685521A5080622031 @default.
- W2099685521 hasAuthorship W2099685521A5089571151 @default.
- W2099685521 hasConcept C125567185 @default.
- W2099685521 hasConcept C126322002 @default.
- W2099685521 hasConcept C126894567 @default.
- W2099685521 hasConcept C142724271 @default.
- W2099685521 hasConcept C204787440 @default.
- W2099685521 hasConcept C27081682 @default.
- W2099685521 hasConcept C2777562237 @default.
- W2099685521 hasConcept C2777590997 @default.
- W2099685521 hasConcept C2778822586 @default.
- W2099685521 hasConcept C2779929075 @default.
- W2099685521 hasConcept C2780816001 @default.
- W2099685521 hasConcept C71924100 @default.
- W2099685521 hasConcept C84393581 @default.
- W2099685521 hasConcept C87813604 @default.
- W2099685521 hasConceptScore W2099685521C125567185 @default.
- W2099685521 hasConceptScore W2099685521C126322002 @default.
- W2099685521 hasConceptScore W2099685521C126894567 @default.
- W2099685521 hasConceptScore W2099685521C142724271 @default.
- W2099685521 hasConceptScore W2099685521C204787440 @default.
- W2099685521 hasConceptScore W2099685521C27081682 @default.
- W2099685521 hasConceptScore W2099685521C2777562237 @default.
- W2099685521 hasConceptScore W2099685521C2777590997 @default.
- W2099685521 hasConceptScore W2099685521C2778822586 @default.
- W2099685521 hasConceptScore W2099685521C2779929075 @default.
- W2099685521 hasConceptScore W2099685521C2780816001 @default.
- W2099685521 hasConceptScore W2099685521C71924100 @default.
- W2099685521 hasConceptScore W2099685521C84393581 @default.
- W2099685521 hasConceptScore W2099685521C87813604 @default.
- W2099685521 hasIssue "3" @default.
- W2099685521 hasLocation W20996855211 @default.
- W2099685521 hasLocation W20996855212 @default.
- W2099685521 hasOpenAccess W2099685521 @default.
- W2099685521 hasPrimaryLocation W20996855211 @default.
- W2099685521 hasRelatedWork W1984567959 @default.
- W2099685521 hasRelatedWork W2064883997 @default.
- W2099685521 hasRelatedWork W2131071144 @default.
- W2099685521 hasRelatedWork W2359749915 @default.
- W2099685521 hasRelatedWork W236923098 @default.
- W2099685521 hasRelatedWork W2411457951 @default.
- W2099685521 hasRelatedWork W2413319831 @default.
- W2099685521 hasRelatedWork W2417949794 @default.
- W2099685521 hasRelatedWork W2620761541 @default.
- W2099685521 hasRelatedWork W4252322895 @default.
- W2099685521 hasVolume "180" @default.
- W2099685521 isParatext "false" @default.
- W2099685521 isRetracted "false" @default.
- W2099685521 magId "2099685521" @default.